Clostridium butyricum and Reduced Depression Symptoms

Doses used in studies

mg/day: 60 (median 60, IQR 60–60) — 1 study

Time to effect

Median: 8 weeks · IQR 8 weeks–8 weeks · Range 8 weeks–8 weeks — Reported in 1 of 1 study

1 of 1 paper

Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial.

2018-09
RCT · n = 20
Clinical neuropharmacology 41(5)
- Tsuyoshi Miyaoka
- Misako Kanayama
- Rei Wake
- Sadayuki Hashioka
- Maiko Hayashida
- Michiharu Nagahama
- Shihoh Okazaki
- Satoko Yamashita
- Shoko Miura
- Hiroyuki Miki
- Hiroyuki Matsuda
- Masahiro Koike
- Muneto Izuhara
- Tomoko Araki
- Keiko Tsuchie
- Ilhamuddin Abdul Azis
- Ryosuke Arauchi
- Rostia Arianna Abdullah
- Arata Oh-Nishi
- Jun Horiguchi

PubMed: 30234616
DOI: 10.1097/wnf.0000000000000299

5 Insights on

Reduced Depression Symptoms

High evidence
Highly Cited
Clinical

CBM588 (60 mg/d) in combination with antidepressants provided significant improvement in depression as measured by the Beck Depression Inventory from baseline to week 8.

Effect: Beneficial
Effect size: Small
Significant: Yes
Dose: 60 mg/d